logowsbdaily | Fri, 03 Dec 2021 08:39:03 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Citius Pharmaceuticals, Inc.
(CTXR)

Citius Pharmaceuticals, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-base... Read More

Summary & Charts

Price$ 1.58-0.02 (-1.25%)
Day's Range$ 1.56 - 1.62 
Previous Close$ 1.60
Market Cap$ 248.16M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume2.55M
Avg. Volume (20 day)1.79M
Rel. Volume (20 day)1.42
Rel. Volume (3 month)1.19
RatingB+Buy
DCFN/AStrong Buy
Debt/Equity6.81 %Neutral
ROE-27.71 %Neutral
ROA-17.46 %Neutral
P/E-9.76 %Strong Sell
P/B1.59 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Dec 02, 2021$ 1.61$ 1.62$ 1.56$ 1.58-0.022,553,9201.421.191
Dec 01, 2021$ 1.73$ 1.73$ 1.60$ 1.60-0.091,939,6311.090.88
Nov 30, 2021$ 1.66$ 1.73$ 1.62$ 1.69+0.072,420,0151.391.046
Nov 29, 2021$ 1.68$ 1.70$ 1.61$ 1.62-0.061,856,7301.100.78
Nov 26, 2021$ 1.69$ 1.72$ 1.65$ 1.68-0.041,074,4390.640.453
Nov 24, 2021$ 1.67$ 1.74$ 1.66$ 1.72+0.04926,4730.540.39
Nov 23, 2021$ 1.69$ 1.71$ 1.66$ 1.68-0.021,074,8030.630.442
Nov 22, 2021$ 1.72$ 1.73$ 1.66$ 1.70-0.011,966,4891.110.817
Nov 19, 2021$ 1.70$ 1.74$ 1.69$ 1.71+0.021,466,5580.800.612
Nov 18, 2021$ 1.77$ 1.77$ 1.67$ 1.69-0.072,246,0141.070.933
Nov 17, 2021$ 1.78$ 1.80$ 1.75$ 1.76-0.021,558,1950.750.64
Nov 16, 2021$ 1.80$ 1.81$ 1.77$ 1.78-0.032,015,0620.970.813
Nov 15, 2021$ 1.83$ 1.84$ 1.80$ 1.81-0.021,411,4220.690.571
Nov 12, 2021$ 1.81$ 1.84$ 1.80$ 1.83+0.011,494,8650.720.602
Nov 11, 2021$ 1.84$ 1.90$ 1.81$ 1.82+0.011,872,7420.890.742
Nov 10, 2021$ 1.89$ 1.92$ 1.80$ 1.81-0.115,245,0642.372.071
Nov 09, 2021$ 1.93$ 1.95$ 1.88$ 1.92-0.011,392,7900.660.562
Nov 08, 2021$ 1.91$ 1.94$ 1.91$ 1.93-0.021,254,5880.600.50
Nov 05, 2021$ 1.93$ 1.98$ 1.91$ 1.95980,5540.470.39
Nov 04, 2021$ 1.97$ 1.99$ 1.93$ 1.95-0.031,130,0180.540.444

News

The latest news about Citius Pharmaceuticals, Inc. (CTXR).

PRNewsWire | 2021-10-25 09:15:00
CRANFORD, N.J., Oct. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.
PennyStocks | 2021-10-17 17:00:00
Which penny stocks are on your watchlist for this coming week? The post Top Penny Stocks to Add to Your Watchlist This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PRNewsWire | 2021-10-13 11:38:00
CRANFORD, N.J., Oct. 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m.
PRNewsWire | 2021-10-06 10:40:00
CRANFORD, N.J., Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
PRNewsWire | 2021-10-01 08:30:00
CRANFORD, N.J., Oct. 1, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University , Philadelphia, PA, which renamed the main building housing the College of Liberal Arts (CLA) to Leonard and Helena Mazur Hall in recognition of the Mazur's longstanding commitment to Temple University's students and alumni.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-12-14BMO-0.04----------
2021-08-12BMO-0.05-0.05--------
2021-05-13BMO-0.07-0.0442.86%------
2021-02-11BMO0.16-0.15-193.75%------
2020-08-14BMO-0.1-0.119.99%------
2020-05-14BMO-0.1-0.1330%------
2020-02-13BMO-0.14-0.157.14%------
2019-12-16BMO-0.14-0.1614.28%------

Top Discussions

These are the top discussions over the last 24-hours that mention the CTXR stock ticker symbol.

Daily Plays December 02, 2021

Talk about your plays today or things you are on the lookout for. This is where you belong if your comment includes a $Ticker in that format. ​ *keep it civil please*...

59 comments | 0 votes


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Fri, 29 Oct 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.